Mechanism of Epigallocatechin-3-gallate on Amelioration of Experimental Autoimmune Encephalomyelitis

SUN Quan-ye,ZHANG Xia,ZHENG Ying-xia,HU Xiao-juan,CHEN Ming,NIE Hong

2010-01-01

Abstract:To investigate the mechanism of epigallocatechin-3-gallate(EGCG) for the treatment of experimental autoimmune encephalomyelitis(EAE),the EAE mouse model was established by immunization of mice with MOG_(35-55) peptide.The proliferation of MOG-specific T cells in EGCG-treated and control mice was investigated by ~3H-TdR mcorporation.ELISA assay was used to detect the contents of IFN-γ,TNF-αand IL-4 proteins in the culture supernatants and Western blot assay was applied to investigate the IKK and IκB protein expressions in NF-κB signal pathway.Meanwhile,the mRNA expression level of T-bet and GATA-3 gene was determined by real-time PCR.The experimental results showed that in vivo treatment of EAE mice with EGCG had great therapeutical benefit at clinical levels.Disease suppression was found to be associated with inhibition of MOGspecific T cell proliferation with down-regulation of the expression of inflammatory cytokines including IFN-γand TNF-αas well as with the up-regulation of the expression of anti-inflammatory cytokine IL-4.In vivo treatment of EAE mice with EGCG resulted in intracellular accumulation of IκB through decreasing IKK phosphorylation and subsequent inhibition of NF-κB activation and induced the gene expression shift of the specific transcription factor(T-bet and GATA-3) in Th1 and Th2 cell differentiation. In conclusion,our study provides experimental evidence that EGCG had great therapeutic effect on EAE by its inhibition action on pathogenic T cells,through a specific effect on the Th1/Th2 shift and induction of IκB expression to inhibit nuclear translocation of NF-κB.These results suggest that EGCG may be of potential therapeutic value for the treatment of autoimmune disorders.